Recent Updates
Recently added Catalysts
SRRK Positive Sentiment

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Friday, August 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Scholar Rock has provided an update on its regulatory progress for apitegromab, a treatment for spinal muscular atrophy (SMA). The company has successfully removed Catalent Indiana LLC as a commercial fill-finish facility from its Biologics License Application (BLA). This move is expected to enhance the efficiency of the regulatory process.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scholar Rock is making progress in regulatory submissions.
  • The removal of Catalent may streamline the BLA process.
  • Focus on improving lives of patients with rare neuromuscular diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.7%
average across 5 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Apitegromab
Phase 3 · Spinal Muscular Atrophy

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced it has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for the treatment of spinal muscular atrophy (SMA) in

Frequently Asked Questions

What is the purpose of Scholar Rock's apitegromab?

Apitegromab is aimed at treating spinal muscular atrophy (SMA).

Who was removed from the BLA process?

Catalent Indiana LLC was removed as a commercial fill-finish facility.

What does the removal of Catalent mean for the BLA?

It may streamline the regulatory process for Scholar Rock's application.

What is Scholar Rock's focus?

The company focuses on patients with rare, severe neuromuscular diseases.

ShareAdd on Google
Tags: SRRK Viatris Investor Conferences Healthcare Scholar Rock apitegromab SMA regulatory progress Catalent
Last updated: Aug 21, 2026

Biotech snapshot

Cash runway
$492M liquidity · $36M/mo burn
~13 mo
Low dilution risk
Lead asset
ApitegromabPhase 3
Spinal Muscular Atrophy →

Catalyst track record

+68%
best trade around SRRK's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for SRRK.

See every catalyst's timing & PoA →